



Lymphedema and Lymphatic Surgery: An Overview

Roman Skoracki, MD, FRCSC, FACS

Professor

Division Chief of Reconstructive Oncologic Plastic Surgery

Department of Plastic Surgery

The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

 **THE OHIO STATE UNIVERSITY**
WEXNER MEDICAL CENTER

No Disclosures

What is lymphedema?

3


Lymphedema

- Physically, functionally & psychologically debilitating
 - Heavy, swelling
 - Deforming
 - Painful
 - Infection
- Life-long, chronic disability, financial cost



Background

- Lymphedema is a chronic, debilitating condition that affects about 250 million people worldwide.



Lymphedema: Pathophysiology and clinical manifestations. Grada A, Phillips T. Journal of the American Academy of Dermatology. Volume 77, Issue 6, December 2017, Pages 1009-1020

5


Types of lymphedema

- **Primary lymphedema**
 - Born with no or abnormal lymphatic system
 - Frequently symptomatic during teenage years
- **Secondary lymphedema**
 - The most common
 - Normal lymphatic system has been disrupted
 - Cancer treatment (lymph node removal, chemotherapy, radiation therapy, Trauma, Infection etc.



6

Primary lymphedema



7


Secondary lymphedema

- The most common cause of lymphedema is lymphatic filiaris (LF) – roundworm, which affects 120 million people and is mostly limited to tropical countries.



8

Secondary lymphedema – cancer related



- 40-70% (breast/melanoma) will develop lymphedema after lymph node dissection

9

Lymphedema

- United States
 - Highest number in breast cancer patients
 - ALND & XRT
 - ~10%-40%
 - SLND
 - ~5-10%
 - ~ 1:4-5 patients treated for breast cancer will develop arm lymphedema



Patients with secondary lymphedema



11

Cost of lymphedema

- Lymphedema increases treatment costs by ~\$10,000 per year per patient
 - Functional impairment
 - Susceptible to infection
 - Negative psychosocial impact
- Managing “lymphedema is worse than having cancer” due to “perpetual discomfort”



12

How to stage lymphedema?

13


The International Society of Lymphology Staging

Stage 0 – subclinical - patients' self-reported symptoms are accurate indicators of early lymphedema. May be detected with bioimpedance and perometry.


Stage 1 – Pitting edema that subsides with elevation of the affected part

Stage 2 – Pitting edema that may improve, but does not resolve, with elevation. In later stages fibrosis develops.

Stage 3 – The tissue in this stage becomes harder (more fibrotic) and pitting is absent. Swelling may lead to extreme volume excess. Skin changes may be present such as thickening, hyper-pigmentation, increased (deepened) skin folds, fat deposits and warty overgrowths. Elephantiasis




Video - ICG (Indocyanine Green) Lymphography



15

Staging According to Dermal Backflow Patterns




Early Diagnosis and Risk Factors for Lymphedema following Lymph Node Dissection for Gynecologic Cancer. Akita, Mitsukawa, Rikihisa, Kubota, Omori, Mitsuhashi, Tate, Shozu, Satoh. PRS Feb 2013

How to treat lymphedema?

17

Treatment Options



18

Complex decongestive therapy



Lymphcare.com

19


TREATMENT OPTIONS FOR PATIENTS WHO DO NOT IMPROVE WITH CDT

Surgical lymphedema treatment is considered, if:

The patient and the lymphedema therapist are dissatisfied with the result achieved with CDT alone after at least 3 months of compliant therapy during which the patient has plateaued or worsened

Surgical Treatment Options

Lymphedema



21

ISL Stage 0

22

Stage 0

- **Pre-clinical**
 - Certified lymphedema therapist referral for teaching and possibly compression for high risk activity
 - Consider ICG lymphogram for staging and LVB if Stardust or diffuse pattern
 - Close surveillance for signs of progressive lymphedema
 - Consider annual ICG lymphograms for surveillance

23

ISL Stage 1


24

Stage 1

- Early lymphedema – reversible with elevation
 - Candidate for LVB on ICG lymphogram
 - Lymphovenous bypass (LVB)

25

Lymphovenous Bypass




26



Isao Koshima, Kiichi Inagawa,
Katsuyuki Urushibara,
and Takahiko Moriguchi

SUPERMICROSURGICAL
LYMPHATICOVENULAR
ANASTOMOSIS FOR THE
TREATMENT OF LYMPHEDEMA IN
THE UPPER EXTREMITIES




- Subdermal lymphatics to subdermal venules
- “super-microsurgery”
 - < 0.8 mm

Lymphatic mapping



- Lymphatic mapping with ICG angiography
- Identify areas of dermal reflux and available lymphatic channels
- “Roadmap for LVB”



Lymphovenous bypass



- Supermicrosurgery
- Specialized microscope
- Incision length: 2-3 cm
- 11-0 or 12-0 nylon, 50 μ needle


29

Types of lymphovenous bypass




30

Types of lymphovenous bypass



31

MDACC Stage 1 Pre/Post Op



32

MDACC Stage 2 Pre/Post Op



33

MDACC Stage 3 Pre/Post Op



34

RECONSTRUCTIVE ■

A Prospective Analysis of 100 Consecutive Lymphovenous Bypass Cases for Treatment of Extremity Lymphedema

David W. Chang, M.D.
Hiroo Suami, M.D., Ph.D.
Roman Skoracki, M.D.
Houston, Texas


Background: The authors prospectively evaluated the efficacy of lymphovenous bypass in patients with lymphedema secondary to cancer treatment.
Methods: The authors prospectively enrolled 100 consecutive patients with extremity lymphedema secondary to cancer treatment. Sixty-five patients

- 96 % symptomatic improvement
- 74 % with quantitative improvement
 - Upper Extremity mean volume differential reduction was 42 % at 12 months
 - Stage 1 & 2 – 61%
 - Stage 3 & 4 - 17%

Prophylactic lymphovenous bypass

- For patients who will have complete lymph node basin resection in high-risk patient (anticipated or delivered radiation therapy and chemotherapy)
- **Prophylactic LVB or Immediate Lymphatic Reconstruction is offered**

Prophylactic LVB



37

LYMPHATIC MICROSURGICAL PREVENTING HEALING APPROACH (LYMPHA) FOR PRIMARY SURGICAL PREVENTION OF BREAST CANCER-RELATED LYMPHEDEMA: OVER 4 YEARS FOLLOW-UP

FRANCESCO BOCCARDO M.D., Ph.D.,^{1*} FEDERICO CASABONA M.D.,² FRANCO DeCIAN M.D.,³ DANIELE FRIEDMAN M.D.,⁴ FEDERICA MURELLI M.D.,⁴ MARIA PUGLISI M.D.,⁴ CORRADO C. CAMPISI M.D.,³ LIDIA MOLINARI M.D.,¹ STEFANO SPINACI M.D.,¹ SARA DESSALVI M.D.,¹ and CORRADINO CAMPISI M.D., Ph.D., F.A.C.S.¹

- 74 patients
 - 47% had radiation
 - 96% of patients with no signs of lymphedema
 - 4% of patients developed lymphedema 8-12 months after surgery

38



LYMPHA Technique to Prevent Secondary Lower Limb Lymphedema

Francesco Boccardo, MD, PhD¹, Mario Valenzano, MD², Sergio Costantini, MD², Federico Casabona, MD², Matteo Morotti, MD², Paolo Sala, MD², Franco De Cian, MD³, Lidia Molinari, MD¹, Stefano Spinaci, MD¹, Sara Dessalvi, MD¹, Corrado Cesare Campisi, MD¹, Giuseppe Villa, MD⁴, and Corradino Campisi, MD, FACS¹

- 11 vulvar cancer and 16 melanoma of the trunk - inguinofemoral lymphadenectomy
 - No lymphocele or infectious complications
 - Transient edema in one melanoma patient
 - Lymphedema in one patient (9 %) with vulvar cancer.

ISL Stage 2

Stage 2

- Lymphedema that does not resolve with elevation alone


Pitting
Edema

Non-Pitting
Edema

41

Types of Vascularized Lymph Node Transfer


- Groin
- Axilla
- Supraclavicular
- Submental
- Omental
- Jejunal mesenteric



Jejunal Mesenteric Lymph Node Transfer

- Advantages
 - Multiple flaps of 3-5 nodes can be harvested
 - Small size (4x3x2cm) ideal for distal placement of nodes
 - Avoid iatrogenic donor site lymphedema

- Disadvantages
 - No skin island
 - Require laparotomy



43

Pre-operative Considerations

- Relative contraindications
 - History of multiple previous open laparotomies
 - Intra-abdominal radiation
 - Ventral hernia repair

- Absolute contraindication
 - Multiple hernia repairs
 - Previous adhesive bowel obstruction


44

Video - Surgical Approach



*Courtesy of Dr. Roman Skoracki


Peripheral Mesenteric Node VLNT



Distal vs. Proximal VLNT Placement

Proximal

- Release of scar with placement of healthy well vascularized tissue
 - Release of potential venous compression from scar with soft tissue fill




47

Distal vs. Proximal VLNT Placement

Distal

- Site of greatest fluid accumulation / most dependent
- Greatest volume reduction, especially early



48

Flap Revascularized



Flap Inset and Skin Graft



Mesenteric VLNT Outcome


Pre-op			8 months	
Middle finger left	6.4		Middle finger left	6.4
Palmer crease left	19.6		Palmer crease left	19
Wrist left	19.6		Wrist left	17.4
Forearm left	27.6		Forearm left	26
Elbow left	28		Elbow left	27
Mid-upper arm left	32.8		Mid-upper arm left	30
Axilla left	36.6		Axilla left	35

Patient describes extremity as much softer and wears compression only occasionally

Postoperative Considerations


- Admitted for free flap monitoring
- Diet is advanced from clears as tolerated
- Axilla
 - Arm abducted with an abduction pillow x 1 week
- Groin
 - Avoid hip flexion >45 degrees x 1 month
- Distal leg
 - Dangle protocol

Omental VLNT



53

Simultaneous double level VLNT



54


Patients with non-pitting edema

- Most likely secondary to soft tissue hypertrophy
- Are candidates for non-physiological surgery
 - Liposuction
 - Debulking



55

Liposuction



56

Pre and Post-operative Liposuction



57



REVIEW ARTICLE

Lymphedema *A Comprehensive Review*

Anne G. Warren, BA, Håkan Brorson, MD, PhD,‡ Loren J. Borud, MD,†
and Sumner A. Slavin, MD†*

106% mean edema volume reduction at 10 years


Issues:

- Permanent need for garments (discontinuation of garment = recurrence)
- multiple incisions 15-20
- New compression stocking every 3 months

ISL Stage 3

59

Charles Procedure



- Circumferential excision of skin, subcutaneous tissue and deep fascia
- Coverage with split or full thickness skin grafts

Intraoperative photographs



Pre and Post-op Charles Procedure



Conclusion

- Lymphedema treatment can be personalized based on the severity and stages of patient's lymphedema
- It is critical to recognize, and initiate indicated treatments early to maximize patient's outcomes